Skip to main content

Base de données Acteurs et réseaux

Le domaine en pleine évolution de thérapies géniques et cellulaires est soutenu par une large communauté d’organismes universitaires, cliniques, translationnels, réglementaires et de patients. La base de données Acteurs et réseaux répertorie ces acteurs en Europe et au-delà, leurs activités et les ressources qu'ils ont produites.

EuroGCT a produit et compilé cette base de donnée pour ceux qui souhaitent identifier les acteurs impliqués à chaque étape du parcours menant les thérapies géniques et cellulaires du laboratoire à la clinique. D'un point de vue académique, notre objectif est de cartographier les informations qui n'ont pas encore été cartographiées ailleurs.

Cela comprend la documentation des différents types de régulateurs interconnectés, des groupes de patients activement impliqués dans les parcours de soins et des organisations à but non lucratif consacrées au développement de thérapies. Dans sa première version, cette base de données ne comprend pas encore les partenaires commerciaux et les prestataires de services.

Des travaux complémentaires réalisés par d'autres organisations sur la cartographie des parties prenantes des thérapies géniques et cellulaires peuvent être trouvées ici.

Un article scientifique sur les acteurs a également été publié dans Humanities and Social Sciences CommunicationsLien vers son résumé grand public. 

Showing 10 of 400

3EC International a.s.

Region/Country:  
  • Countries in the EU/EEA
  • Slovakia

Type of Actor:

  • Regulators
  • Medical Devices Entities
  • Notified Bodies

Development Stage:

  • Manufacturing
  • Commercialisation

Action Duchenne

Region/Country:  
  • EU/EEA

Type of Actor:

  • Patient Organisations
  • Regional/Local Patient Organisations

Development Stage:

  • Patient and Public Involvement

Conditions and Diseases:

  • Muscle and Skeletal Diseases
  • Rare diseases

Additional information

Action Duchenne is a charity that supports families and individuals affected by Duchenne muscular dystrophy (DMD), a rare and progressive muscle-wasting condition.

Advanced Therapy Treatment Centre (ATTC)

Region/Country:  
  • UK

Type of Actor:

  • Networks
  • European and Regional Networks
  • Non-profit Research Organisations
  • National Research Centres
  • Research Hospitals

Development Stage:

  • Clinical Research
  • Translational Research
  • Manufacturing
  • Commercialisation

Additional information

The ATTC network is a UK wide group of Advanced Therapy Treatment Centres operating within the NHS framework. It aims to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients.

AFM-Téléthon

Region/Country:  
  • Countries in the EU/EEA
  • France

Type of Actor:

  • Patient Organisations
  • Regional/Local Patient Organisations

AFNOR Certification

Region/Country:  
  • Countries in the EU/EEA
  • France

Type of Actor:

  • Regulators
  • Medical Devices Entities
  • Notified Bodies

Development Stage:

  • Manufacturing
  • Commercialisation

Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (Javna agencija Republike Slovenije za zdravila in medicinske pripomočke) (JAZMP)

Region/Country:  
  • Countries in the EU/EEA
  • Slovenia

Type of Actor:

  • Regulators
  • HTA Bodies
  • Medicines Agencies
  • National Medicines Agencies
  • Medical Devices Entities
  • Medical Device Authorities
  • National Medical Device Authorities
  • Other National competent authorities
  • Competent Authorities for Tissues and Cells
  • Competent Authorities for Blood and Blood Components
  • Competent Authorities for GMO

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Manufacturing
  • Commercialisation

Additional information

According to the JAZMP Website: “In the Republic of Slovenia, HTA is currently not performed in a dedicated HTA institution. JAZMP is currently not an HTA competent authority, but is in the position to perform HTA-related tasks in pricing procedures as defined in Article 182 of the Medicinal Products Act (Uradni list RS [Official Gazette of the Republic of Slovenia], No. 17/14 and 66/19).” (https://www.jazmp.si/en/human-medicines/health-technology-assessment/)

All Wales Therapeutics and Toxicology Centre (AWTTC)

Region/Country:  
  • UK

Type of Actor:

  • Regulators
  • HTA Bodies

Development Stage:

  • Commercialisation

Alliance for Regenerative Medicine (ARM)

Region/Country:  
  • Global

Type of Actor:

  • Networks
  • Other International Networks

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Translational Research
  • Manufacturing
  • Commercialisation

Additional information

ARM is an international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM represents the interests of 400+ members across 25 countries, including small and large companies, academic research institutions, major medical centers and patient groups.

Amgros

Region/Country:  
  • Countries in the EU/EEA
  • Denmark

Type of Actor:

  • Regulators
  • HTA Bodies

Development Stage:

  • Commercialisation

Association of the British Pharmaceutical Industry (ABPI)

Region/Country:  
  • UK

Type of Actor:

  • Networks
  • European and Regional Networks

Development Stage:

  • Clinical Research
  • Translational Research
  • Manufacturing
  • Commercialisation
  • Patient and Public Involvement

Additional information

The Association of the British Pharmaceutical Industry is the trade association for over 120 companies in the UK producing prescription medicines for humans